APLMW (Apollomics) Revenue: $8.50 Mil (TTM As of Dec. 2025)


APLMW Apollomics Inc APLMW
30 GF Score
Price $0.01
! 4 Warning Signs
View Full Analysis

What is Apollomics Revenue?

Apollomics APLMW 30 Revenue is $8.50 Mil as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 30/100. The stock has 4 warning signs investors should review.

Apollomics's revenue for the six months ended in Dec. 2025 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $8.50 Mil. Apollomics's Revenue per Share for the six months ended in Dec. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.10.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Apollomics  (NAS:APLMW) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Apollomics Revenue Related Terms

Apollomics Revenue Historical Data

* Premium members only.

The historical data trend for Apollomics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Revenue Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 8.50

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 8.50 0.00

APLMW vs HYPD, MGX, KALA: Revenue Comparison

For the Biotechnology subindustry, Apollomics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollomics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apollomics's Revenue distribution charts can be found below:

* The bar in red indicates where Apollomics's Revenue falls into.


APLMW
30GF Score
Apollomics Inc APLMW
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $8.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $8.50 Mil mean?
Apollomics (APLMW) has a Revenue of $8.50 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Apollomics and its competitors.
Is Apollomics' Revenue too high?
Apollomics' current Revenue is $8.50 Mil. Overall, Apollomics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Revenue compare to HYPD and MGX?
Apollomics' Revenue of $8.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Apollomics and its competitors. Apollomics's current Revenue is $8.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Revenue of $8.50 Mil. The current Revenue is $8.50 Mil. Apollomics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Apollomics (APLMW), the current Revenue is $8.50 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
30GF Score

Get the complete analysis for APLMW

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price